Esteban Santos - Amgen Executive Vice President Operations

AMGN Stock  MXN 5,779  94.00  1.65%   

President

Mr. Esteban Santos is the Executive Vice President, Operations of the Company. Mr. Santos became Executive Vice President, Operations in July 2016. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. From October 2008 to May 2013, Mr. Santos held a number of Vice President roles at the Company in engineering, manufacturing, site operations and drug product. From May 2013 to July 2016, Mr. Santos was Senior Vice President, Manufacturing. Prior to joining the Company, Mr. Santos served as Site General Manager for JJs Cordis operation in Puerto Rico. Prior to JJ, Mr. Santos held several management positions in GEs industrial and transportation businesses. since 2016.
Age 55
Tenure 8 years
Phone805 447 1000
Webhttps://www.amgen.com

Amgen Management Efficiency

The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.
Amgen Inc has accumulated 37.35 B in total debt with debt to equity ratio (D/E) of 309.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has a current ratio of 2.71, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Amgen until it has trouble settling it off, either with new capital or with free cash flow. So, Amgen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amgen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amgen to invest in growth at high rates of return. When we think about Amgen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Joel PoppenMicron Technology
54
Michael BokanMicron Technology
62
David ZinsnerMicron Technology
49
Scott DeBoerMicron Technology
57
Joanne SmithDelta Air Lines
60
Matthew EllisVerizon Communications
52
Wayne WestDelta Air Lines
58
Manish BhatiaMicron Technology
51
Brady ConnorVerizon Communications
N/A
James ClarkCVS Health
58
Hans VestbergVerizon Communications
58
Steven SearDelta Air Lines
53
Rahul SamantDelta Air Lines
56
Sumit SadanaMicron Technology
54
Peter CarterDelta Air Lines
59
April ArnzenMicron Technology
47
Paul JacobsonDelta Air Lines
47
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. AMGEN INC operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 21500 people. Amgen Inc (AMGN) is traded on Mexican Exchange in Mexico and employs 25,200 people.

Management Performance

Amgen Inc Leadership Team

Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Louie, VP Officer
Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
Murdo Gordon, Executive Vice President of Global Commercial Operations
Peter Griffith, Ex CFO
Esteban Santos, Executive Vice President Operations
Jonathan Graham, Senior Vice President General Counsel, Secretary
Nancy Grygiel, Sr Officer
Mike Zahigian, VP Officer
David MD, Ex RD
Arvind Sood, IR Contact Officer

Amgen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Amgen Stock Analysis

When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.